Track market-moving stories before they get noisy

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter financial and operating results after the market close on Thursday, August 6, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-579-2543 or 1-785-424-1789 and reference Maravai.

-

New Jupiter, FL facility enables RNA therapeutics developers to source critical manufacturing materials from a single, coordinated supplier, simplifying workflows and accelerating development timelines.

JUPITER, Fla.--(BUSINESS WIRE)--TriLink, part of Maravai LifeSciences® (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA therapeutic developers simplify sourcing and scale production more efficiently. The facility supports a coordinated supply of key RNA manufacturing and IVT workflow materials from early research through commercial production.

The launch addresses a long-standing pain point for RNA therapeutics developers sourcing critical raw materials — enzymes, nucleotides, cap analogs, and tail technology — from multiple vendors with different quality systems, timelines, and points of contact. Managing different quality systems, timelines, and supply processes can slow development and create manufacturing risk. TriLink is now offering these materials as a coordinated, single-source package designed to simplify development and scale up.

The Jupiter facility was purpose-built for GMP enzyme manufacturing. It features controlled cleanroom environments, validated production processes, and scalable capacity designed to support both clinical-stage programs and commercial supply. Full traceability and quality systems are in place to meet regulatory requirements across major markets.

The facility is already supporting customer programs, with TriLink successfully shipping its first commercial GMP enzyme batch in June 2026. This milestone demonstrates the facility’s operational readiness and ability to provide commercial-scale supply of critical IVT raw materials to RNA therapeutics developers worldwide.

The facility’s flagship product is GMP CleanScribe™ RNA Polymerase that reduces double-stranded RNA (dsRNA) formation by up to 85% compared to standard Wild-type T7 RNA polymerases, a result demonstrated across internal and customer studies. dsRNA is a critical quality attribute in therapeutic mRNA manufacturing: its accumulation drives purification complexity, depresses final RNA purity, and increases immunogenicity risk in vivo. CleanScribe™ RNA Polymerase is engineered specifically for IVT workflows where controlling dsRNA at the synthesis step translates directly into downstream process efficiency and product quality.

An Integrated IVT Raw Materials Solution

TriLink BioTechnologies is now offering a coordinated supply of GMP-grade IVT raw materials:

GMP CleanScribe™ RNA Polymerase Mix GMP NTPs (nucleoside triphosphates) GMP CleanCap® analogs — the industry-standard co-transcriptional capping reagents GMP ModTail™ technology — designed to enhance mRNA stability and in vivo protein expression The integrated offering is designed to reduce vendor complexity, simplify tech transfer, and ensure material consistency across the development lifecycle from IND-enabling studies through BLA submission and commercial launch.

As RNA-based therapeutics move into later-stage clinical development and commercial production, reliable access to manufacturing materials becomes increasingly important. Enzyme performance variability, regulatory gaps in supplier quality systems, and multi-vendor logistics create compounding delays at precisely the stages when speed matters most.

Combining GMP manufacturing, high-performance enzyme design, and coordinated supply with TriLink’s other GMP consumables, is intended to compress this complexity into a single, accountable partner relationship.

“RNA therapeutics developers need reliable supply partners that can support them from early research through commercial manufacturing. By combining enzyme manufacturing capabilities with TriLink’s existing RNA technologies, we help customers simplify sourcing, reduce supply chain complexity, and accelerate scale-up with greater confidence.”

— Chad Decker, SVP Global Sales, TriLink BioTechnologies

To learn more about TriLink’s new GMP enzyme capabilities visit: https://www.trilinkbiotech.com/gmp-enzymes

About TriLink BioTechnologies

TriLink BioTechnologies, part of Maravai LifeSciences, is a global leader in nucleic acid technologies and manufacturing solutions for RNA therapeutics, vaccines, gene editing, and diagnostics. The company's portfolio includes modified nucleotides, mRNA products, proprietary technologies such as CleanCap® capping analogs and ModTail™ technology, and a growing portfolio of high-performance enzymes marketed under the Alphazyme brand. Supported by robust GMP manufacturing capabilities, TriLink enables customers from early-stage research through commercial production.

About Maravai LifeSciences

Maravai LifeSciences is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies.

More News From Maravai LifeSciences

Back to Newsroom

Posted by Defense World Staff on Apr 2nd, 2026

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) was the target of some unusual options trading activity on Wednesday. Traders bought 1,002 put options on the stock. This represents an increase of 1,791% compared to the typical daily volume of 53 put options.

Analysts Set New Price Targets A number of equities analysts have recently weighed in on MRVI shares. Wall Street Zen upgraded Maravai LifeSciences from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Wells Fargo & Company boosted their target price on Maravai LifeSciences from $4.00 to $4.50 and gave the company an “overweight” rating in a research note on Monday, December 15th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Maravai LifeSciences currently has a consensus rating of “Hold” and an average price target of $5.38.

Read Our Latest Stock Report on Maravai LifeSciences

Maravai LifeSciences Price Performance NASDAQ MRVI opened at $2.87 on Thursday. The company has a quick ratio of 5.69, a current ratio of 6.60 and a debt-to-equity ratio of 0.85. The stock has a market capitalization of $737.79 million, a PE ratio of -3.19 and a beta of 0.43. The company has a 50 day moving average price of $3.26 and a two-hundred day moving average price of $3.33. Maravai LifeSciences has a 12-month low of $1.66 and a 12-month high of $4.11.

Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03. The company had revenue of $49.87 million for the quarter, compared to analyst estimates of $49.06 million. Maravai LifeSciences had a negative net margin of 70.40% and a negative return on equity of 22.79%. As a group, equities analysts predict that Maravai LifeSciences will post -0.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Maravai LifeSciences Several institutional investors have recently bought and sold shares of MRVI. Tejara Capital Ltd increased its holdings in shares of Maravai LifeSciences by 26.4% during the 3rd quarter. Tejara Capital Ltd now owns 2,453,441 shares of the company’s stock valued at $7,041,000 after acquiring an additional 511,992 shares during the last quarter. Monaco Asset Management SAM lifted its holdings in Maravai LifeSciences by 315.0% in the 3rd quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company’s stock worth $10,494,000 after purchasing an additional 2,775,372 shares during the last quarter. Immersion Corp lifted its holdings in Maravai LifeSciences by 153.3% in the 2nd quarter. Immersion Corp now owns 990,000 shares of the company’s stock worth $2,388,000 after purchasing an additional 599,164 shares during the last quarter. Royce & Associates LP boosted its position in Maravai LifeSciences by 38.0% during the third quarter. Royce & Associates LP now owns 1,761,764 shares of the company’s stock worth $5,056,000 after purchasing an additional 484,908 shares during the period. Finally, First Eagle Investment Management LLC bought a new stake in Maravai LifeSciences during the third quarter worth approximately $1,294,000. 50.25% of the stock is currently owned by institutional investors.

About Maravai LifeSciences (Get Free Report)

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.

See Also Five stocks we like better than Maravai LifeSciences Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEXenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)

NEXT HEADLINE »Wingstop (NASDAQ:WING) Shares Down 6.4% on Analyst Downgrade

Baxter International (BAX - Free Report) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +15.42%. A quarter ago, it was expected that this drug and medical device maker would post earnings of $0.53 per share when it actually produced earnings of $0.44, delivering a surprise of -16.98%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Baxter, which belongs to the Zacks Medical - Products industry, posted revenues of $2.7 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 3.74%. This compares to year-ago revenues of $2.63 billion. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Baxter shares have lost about 11.6% since the beginning of the year versus the S&P 500's gain of 4.2%.

What's Next for Baxter?While Baxter has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Baxter was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.45 on $2.8 billion in revenues for the coming quarter and $1.91 on $11.33 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 27% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Maravai LifeSciences Holdings, Inc. (MRVI - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on May 7.

This company is expected to post quarterly loss of $0.05 per share in its upcoming report, which represents a year-over-year change of +37.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Maravai LifeSciences Holdings, Inc.'s revenues are expected to be $54.57 million, up 16.5% from the year-ago quarter.

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2026, together with other business updates. Key Financial Results: Revenue of $65.8 million, Net loss of $(6.4) million, and Adjusted EBITDA of $20.3 million; Returned to positive free cash flow, generating $4.2 million in the quarter; and Inc.

2 hours ago

Roots Q1 Earnings Call HighlightsMarketBeat

Roots (TSE:ROOT) reported higher first-quarter sales for fiscal 2026 as growth in its direct-to-consumer business and partner channels helped offset pressure from temporary gross margin headwinds and higher project-related expenses. President and Chief Executive Officer Meghan Roach said the compan

TSE:ROOT

Read Roots Q1 Earnings Call Highlights

2 hours ago

Motorpoint Group H2 Earnings Call HighlightsMarketBeat

Motorpoint Group (LON:MOTR) reported record retail volumes and a sharp increase in profit for its 2026 financial year, with management saying data-led pricing, improved vehicle supply and operational efficiency helped the used-car retailer expand margins while growing sales. Chief Executive Officer

LON:MOTR

Read Motorpoint Group H2 Earnings Call Highlights

Sort By

Time Frame

Alert Type

Keywords

Page 1 of 322

Maravai LifeSciences Holdings, Inc. is upgraded to Buy, driven by operational restructuring, improved guidance, and sector recovery. MRVI raised 2026 revenue guidance to $205–$215M and adjusted EBITDA to $30–$32M, reflecting robust Q1 results and cost savings. TriLink segment showed 15% YoY growth; restructuring actions are delivering over $65M in annual EBITDA savings.

Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that the Company will participate in the following investor conference in June.

On June 4, 2026, at 12:50 p.m. Eastern Time, Raj Asarpota, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City, NY.

A live webcast of the fireside chat will be on the Maravai LifeSciences Investor Relations website, under News & Events, IR Calendar. An archived replay of the webcast will also be available on the website following the event.

About Maravai

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies.

For more information about Maravai LifeSciences, visit www.maravai.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260518944378/en/